Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive that the company has received regulatory approval from the UAE Department of Health to proceed with its Phase 2 clinical trial (SKNJCT-004) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin.

The study will enroll 36 patients across four sites in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, Burjeel Medical City, and American Hospital of Dubai.

SKNJCT-004 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of two dose levels of D-MNA (Dermal Micro-Needle Array) compared to placebo. Participants will be randomly assigned in a 1:1:1 ratio to receive either a placebo (P-MNA), 100μg of D-MNA (low dose), or 200μg of D-MNA (high dose) The 200μg dose was previously tested as the maximum dose in Medicus Pharma’s Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation